Statements (26)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvalYear |
2001
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
B01AX05
|
| gptkbp:CASNumber |
114870-03-0
|
| gptkbp:contraindication |
severe renal impairment
active major bleeding |
| gptkbp:drugClass |
gptkb:anticoagulant
|
| gptkbp:eliminationHalfLife |
17-21 hours
|
| gptkbp:genericName |
gptkb:fondaparinux
|
| gptkbp:hasMolecularFormula |
C31H43N3O49S8
|
| https://www.w3.org/2000/01/rdf-schema#label |
Arixtra
|
| gptkbp:indication |
prevention of venous thromboembolism
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
GlaxoSmithKline
|
| gptkbp:mechanismOfAction |
selective factor Xa inhibitor
|
| gptkbp:pregnancyCategory |
B (US)
|
| gptkbp:routeOfAdministration |
subcutaneous injection
|
| gptkbp:sideEffect |
gptkb:anemia
bleeding injection site reactions |
| gptkbp:usedFor |
treatment of deep vein thrombosis
treatment of pulmonary embolism prevention of deep vein thrombosis |
| gptkbp:bfsParent |
gptkb:fondaparinux
|
| gptkbp:bfsLayer |
7
|